CELU

CELU

Celularity Inc

Celularity Inc. develops off-the-shelf placental-derived cell therapies targeting aging-related and degenerative diseases. Its products include therapies for Crohn's disease, osteoarthritis, and various surgical and wound care solutions, alongside bio banking services.

โš•๏ธ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago โ†’$11today

Score Overview

1 Year
Score
Net Growth-28.14%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-12.79%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score5.9
Net Growth64.38%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth231.17%
Rev Trend60%
Revenue Consistencyโ€”
All Time
Score
Net Growth64.99%
Net Trend67%
Net Income Consistency
Rev Growth123.60%
Rev Trend50%
Revenue Consistency

See the full market ranking โ†’

Celularity Inc fundamental performance

Between 2019 and 2024, revenue grew from $ 21M to $ 54M and net income went from -$ 211M to -$ 57M. Revenue increased in 3 of those 5 years; net income in 3.

Celularity Inc currently holds a 5-year HDB Score of 5.9 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.69โ€”
1 Year2025-08-12
$ 3.06-77.45%
5 Years2021-08-12
$ 64.00-98.92%
All Time2019-08-08
$ 98.00-99.30%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 47M-$ 74M$ 120K
2024$ 54M-$ 57M$ 738K
2023$ 22M-$ 196M
2022$ 17M$ 14M$ 13M
2021$ 21M-$ 100M$ 37M
2020$ 14M-$ 208M$ 54M
IPO2019$ 21M-$ 211M$ 28M

Explore beyond CELU

You're looking at Celularity Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies